This Plain Language Summary of Publication article (PLSP) from Future Oncology tested trastuzumab deruxtecan (T-DXd) in 79 patients from the US and Europe with advanced HER2-positive stomach or gastroesophageal junction cancer that had worsened despite previous trastuzumab treatment.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study’ and was published in The Lancet Oncology.

Visit The Lancet using the link to read the original article.